The risk classification system for localized PCa described by D'Amico et al. (3), which defines low risk as a PSA level<10ng/mL, Gleason score≤6, and clinical stage of T1 to T2a, is one of the most frequently used risk classification systems to determine the need for active surveillance. This evidence concerns the gene KLK3 and posterior cortical atrophy.